Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Clinical trial NCT04665115 · WITHDRAWN

Trial details

NCT number: NCT04665115
Sponsor: Academic and Community Cancer Research United
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Asymptomatic COVID-19 Infection Laboratory-Confirmed B-Cell Neoplasm Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma Symptomatic COVID-19 Infection Laboratory-Confirmed Waldenstrom Macroglobulinemia

Start date: 2020-11-23
Primary completion: 2021-11-19
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.